Curis Revenue
Biotechnology Research • 
Lexington, Massachusetts, United States • 101-200 Employees
Curis revenue & valuation
| Annual revenue | $11,500,000 |
| Revenue per employee | $74,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $36,500,000 |
| Total funding | $34,200,000 |
Key Contacts at Curis
Rachel Blasbalg
Senior Director Human Resources
Julie Fergus
Associate Director, Pharmacovigilance
Tanya Broadbent
Senior Director Program Management
Kristopher Lake
Senior Director, Business Planning & Analysis
Brenda Emerzian
Sr. Director, Tmf Operations
Maria Lamar
Executive Director, Clinical Operations
Norman Neville
Consultant Medical Director, Clinical Development
Lindsay Vicenzi
Member Board Of Directors
Robert Curran
Senior Director, It & Facilities
Elizabeth Martinez
Executive Director Of Global Medical Affairs At Curis
Company overview
| Headquarters | 128 Spring St, Building C - Suite 500, Lexington, Massachusetts 02421, US |
| Phone number | +16175036500 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Clinical Development, Oncology, Drug Development, Immunology, Hematology, Small Molecule |
| Founded | 2000 |
| Employees | 101-200 |
| Socials |
Curis Email Formats
Curis uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@curis.com), used 52.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@curis.com | 52.2% |
{first name}{last name} | johndoe@curis.com | 39.1% |
{first initial}{first initial}{first initial} | jjj@curis.com | 4.3% |
{last name}{last name} | doedoe@curis.com | 4.3% |
About Curis
Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at www.curis.com.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Curis has 26 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Curis's funding history, including investment rounds, total capital raised, and key backers.
Curis Tech Stack
Discover the technologies and tools that power Curis's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Form builders
JavaScript frameworks
JavaScript libraries
Video players
Miscellaneous
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Brazil
Netherlands
Japan
United KingdomFrequently asked questions
4.8
40,000 users
